首页|脊髓灰质炎疫苗不同序贯免疫程序的安全性及基础免疫效果评价

脊髓灰质炎疫苗不同序贯免疫程序的安全性及基础免疫效果评价

扫码查看
目的 评价口服脊髓灰质炎减毒活疫苗(oral live attenuated poliomyelitis vaccine,OPV)和脊髓灰质炎灭活疫苗(inactivated poliomyelitis vaccine,IPV)不同序贯免疫程序的安全性及基础免疫效果.方法 选取上海市浦东新区居住的≥ 2月龄婴儿为研究对象,分别于2、3、4月龄进行OPV全程(O-O-O组)、序贯IPV和OPV(I-I-O组)及IPV全程(I-I-I组)基础免疫程序接种,免疫后由家长通过填写自我观察表进行主动监测相关不良反应.免疫前后经上臂静脉采血,分离血清,微量中和试验法检测血清中脊髓灰质炎病毒中和抗体水平,并计算抗体阳转率及几何平均滴度(GMT).采用Logistic多因素回归法分析组别、性别、户籍、出生体质量和免疫前 Ⅰ/Ⅲ型抗体是否阳性等因素对基础免疫后Ⅰ/Ⅲ型抗体阳转率的影响.结果 O-O-O组有1例嗜睡,1例哭闹;I-I-O组有1例嗜睡;I-I-I组有1例哭闹.O-O-O、I-I-O和I-I-I组免疫前Ⅰ型中和抗体GMT分别为41.39、8.21和12.56,Ⅲ型中和抗体GMT分别为7.57、4.02和8.08,组间差异均无统计学意义(F分别为2.815和0.608,P分别为0.061和0.545).免疫前Ⅰ型抗体阳性率分别为24.04%、34.07%和41.00%,组间差异有统计学意义(x2=13.459,P=0.001);Ⅲ型抗体阳性率分别为13.94%、9.89%和18.00%,差异无统计学意义(x2=5.188,P=0.075).免疫后Ⅰ型中和抗体GMT分别为1 311.84、1 812.59和833.24,Ⅲ型中和抗体GMT分别为911.97、1 752.68和419.50,组间差异均有统计学意义(F分别为76.848和202.632,P均<0.001);免疫后Ⅰ型抗体阳转率分别为98.56%、100%和100%,Ⅲ型抗体阳转率分别为99.04%、100%和99.44%,组间差异均无统计学意义(x2分别为2.973和1.045,P分别为0.122和0.789).组别、性别、户籍、出生体质量和免疫前Ⅰ/Ⅲ型抗体是否阳性对基础免疫后Ⅰ/Ⅲ型抗体阳转率均无影响.结论 3种序贯免疫程序具有良好的安全性,且在基础免疫后均能获得较高的抗体阳转率.
Evaluation of safety and efficacy of basic immunization with different sequential immunization programs of polio vaccine
Objective To evaluate the safety and efficacy of basic immunization with different sequential immunization pro-grams of oral live attenuated poliomyelitis vaccine(OPV)and inactivated poliomyelitis vaccine(IPV).Methods Infants above two months of age residing in Pudong New Area,Shanghai,were selected for the study,and the basic immunization program of OPV full course(O-O-O group),sequential IPV and OPV(I-I-O group),and IPV full course(I-I-I group)were administered at 2,3 and 4 months of age,respectively.Relevant adverse reactions were proactively monitored by the parents of the participants via completing their own self-observation form after immunization.Before and after immunization,blood samples were collected from the upper arm vein,and the serum was separated.The neutralizing antibody levels of poliovirus in serum were measured by micro neutralization test,and the antibody positive rate and geometric mean titer(GMT)were calculated.Logistic multivariate regression analysis was used to research the effects of group,gender,household registration,birth mass and positive rate of type Ⅰ/Ⅲ antibody before immunization on the positive rate of type Ⅰ/Ⅲ antibody after basic imm-unization.Results There were one case of lethargy and one case of crying in O-O-O group,one case of lethargy in I-I-O group,and one case of crying in I-I-I group.The GMTs of type Ⅰ neutralizing antibody in the pre-immunization O-O-O group,I-I-O group,and I-I-I group were 41.39,8.21,and 12.56,and those of type Ⅲ neutralizing antibody were 7.57,4.02 and 8.08,respectively.There was no significant difference in GMT between groups for type Ⅰ and Ⅲ neutralizing antibodies before immu-nization(F=2.815 and 0.608,P=0.061 and 0.545,respectively).The positive rates of type Ⅰ antibody before immunization were 24.04%,34.07%and 41.00%,respectively,with significant difference between groups(x2=13.459,P=0.001).The positive rates of type Ⅲ antibody were 13.94%,9.89%and 18.00%,respectively,with no significant difference(x2=5.188,P=0.075).After immunization,the GMTs of type Ⅰ neutralizing antibody were 1 311.84,1 812.59 and 833.24,and those of type Ⅲ neutralizing antibody were 911.97,1 752.68 and 419.50,respectively,with significant differences between groups(F=76.848 and 202.632,respectively,each P<0.001).After immunization,the positive conversion rates of type Ⅰantibody were 98.56%,100%and 100%,and those of type Ⅲ antibody were 99.04%,100%and 99.44%,respectively,with no significant difference between the two groups(x2=2.973 and 1.045,P=0.122 and 0.789,respectively).In addition,group,gender,household registration,birth mass and positive rate of type Ⅰ/Ⅲ antibody before immunization had no effect on the positive conversion rate of type Ⅰ/Ⅲ antibodyafter basic immunization.Conclusion All three sequential immunization pro-grams achieved good safety and high antibody positive conversion rates after basic immunization.

PoliovirusLive attenuated vaccineInactivated vaccineSequential immunizationSafetyImmunization efficacy

张瑞、邓鹏飞、杨丹丹、薛曹怡、肖绍坦、杨天

展开 >

上海市浦东新区疾病预防控制中心复旦大学浦东预防医学研究院,上海 200136

脊髓灰质炎病毒 减毒活疫苗 灭活疫苗 序贯免疫 安全性 免疫效果

上海市公共卫生三年行动计划浦东新区卫生健康委学科建设计划上海市浦东新区卫生系统优秀青年医学人才培养计划上海市浦东新区疾病预防控制中心科技项目

GWVI-11.2-XD08PWZxk2022-25PWRq2023-29PDCDC-2021-05

2024

中国生物制品学杂志
中华预防医学会,长春生物制品研究所有限责任公司

中国生物制品学杂志

CSTPCD
影响因子:0.417
ISSN:1004-5503
年,卷(期):2024.37(5)
  • 27